Antibody immunity found in ovarian cancer

Antibody immunity found in ovarian cancer

Immunomodulation is an exciting anti-cancer strategy and includes cellular immunity and antibody immunity (humoral immunity). Research has so far focused on T-cell cellular type of immunity, which has been variably effective against cancers and has been specifically disappointing in ovarian cancer. There are other strategies and the immune system is very complex.  The following is a discovery that focuses on antibody or so-called “humoral” immunity against ovarian cancer.  It may add another option, beyond the clinically available immune checkpoint inhibitors like Keytruda.

“A new study from Moffitt Cancer Center in ovarian cancer found that the use of IgA-based antibodies produced by B cells may represent new immunotherapeutic agents for tumors that are resistant to conventional blockade of the immune checkpoint and currently target T cell focus centered approaches.

Immunotherapies are designed to strengthen the body’s T cells to recognize and destroy cancer cells. However, ovarian cancer seems to evade them or remain resistant to their activity. This is despite the fact that most ovarian cancers appear to be infiltrated with activated T cells. As a result, the ovarian patient’s results after immunotherapy have largely proven disappointing.

Researchers at the Moffitt Cancer Center have discovered possible reasons why humoral immunity or antibody-based immunity appears to be associated with better outcomes in some ovarian cancers, potentially opening a new line of therapeutic interventions.

With the help of helper T cells, B cells differentiate into plasma B cells, which can produce antibodies against a specific antigen. Previous research has found that patients with plasma and memory B cells may respond better to immunotherapies

To characterize the role of B cells in ovarian cancer, the Moffitt team analyzed 534 samples from patients with high-grade serous ovarian cancer. As expected, they found that patients with higher levels of B cells or plasma cells derived from B cells had better results

Therefore, it appears that IgA, produced in the ovarian cancer microenvironment, antagonizes ovarian cancer growth by directing the coordinated activity of tumor cells, T cells, and B cells – which is a potential new therapeutic direction.”

To read the full article click the link below.

Source link

Previous articleFlaxseed in your diet may prevent ovarian cancer
Next articleEndometriosis in Caesarean section incision scar
“I help and guide women to beat endometriosis and gynecologic cancers that are associated with endo, like ovarian cancer, using a unique combination of minimally invasive robotic surgery, precision medicine therapies and complementary holistic natural support towards thriving in survivorship." Dr. Vasilev is the only physician triple board certified in Ob-Gyn, Gynecologic Oncology and Integrative & Holistic Medicine in the United States. He is an accomplished advanced robotic master surgeon, and is internationally vetted by iCareBetter ( He serves as Professor at the world-renowned Saint John's Cancer Institute in Santa Monica, California and is Clinical Professor at Loma Linda University School of Medicine. He is former faculty and professor at UC Irvine, UCLA, USC and City of Hope and was the founding Medical Director of Integrative Medicine at Providence Saint John's Health Center. He is an active member of multiple medical societies and has been nationally listed in "Best Doctors" for over 20 years.